Plain-English translation of NCT05845424 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people with signs of early heart disease (calcium deposits in the arteries) should take a stronger combination of cholesterol medications to prevent future heart problems. The study compares rosuvastatin and ezetimibe together at higher doses against the standard approach of prescribing cholesterol medications based on individual risk factors. The goal is to see if this more aggressive treatment prevents heart attacks and strokes in people who don't yet have symptoms.
We know that lowering cholesterol helps prevent heart disease, and doctors use this approach in people who have already had heart attacks. However, it's unclear whether giving these same stronger medications to people without heart disease—but who show early warning signs like calcium in their arteries—can also prevent future problems. This study will help doctors understand the best treatment strategy for this group.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to take either a stronger combination of cholesterol medications (rosuvastatin 20 mg plus ezetimibe 10 mg daily) or follow standard treatment based on your risk factors. You'll take your assigned medication daily and visit the clinic periodically so doctors can check your cholesterol levels, monitor for any side effects, and track your health. The study involves 6,000 people and will last several years as researchers watch to see whether the stronger medication combination reduces the risk of heart disease.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
South Korea